The Impact of Tariff Policies on the Medical and Pharmaceutical industry in the Context of the China-U.S. Trade War
DOI:
https://doi.org/10.61173/2qy86x36Keywords:
tariff policy, medical and pharmaceutical in-dustry, trade warAbstract
In this paper, we focus on the impact of tariff policies set by both China and the US on the medical and pharmaceutical industries during the Sino-US trade war. We divide the paper into three parts. The first part provides a brief introduction to relevant information. The second part concentrates on the negative impact of US tariffs on China’s medical industry. The third part discusses the impact of China’s tariff policies on the US pharmaceutical industry. Through these three parts, we have discussed the impact of tariff policies on both sides of the Sino-US trade war, making people realize that the trade war is not only harmful to one side but also has different degrees of impact on both sides. This also helps people have a better and more comprehensive understanding of the challenges and crises faced by the medical and pharmaceutical industries in the Sino-US trade war.
References
[1] Lingxiu Dong,a Panos Kouvelisa, 2020 A generic drug with the same active ingredient formula-
[2] (How New Tariffs on Chinese Medical Products Will Affect US tion as the branded drug. Generic drugs are usually cheap- Healthcare, 2024) er than brand-name drugs. In the United States, the poor
[3] International Trade Administration. (2020). U.S. Medical depend on it. Tariffs set by the United States and China Devices Industry Assessment. Retrieved from [URL]. for each other have led to generic drugs facing rising in-
[4] U.S. Census Bureau. (2018). U.S. Exports to China by NAICS put prices, and generic drug companies may face greater Medical Devices. Retrieved from [URL]. difficulty in obtaining affordable inputs due to lack of
[5] Mindray Medical International. (2019). Annual Report. intellectual property portfolios to use in intense negotia- Retrieved from [URL]. tions. The FDA estimates that 80 percent of apis used in
[6] Ni, J., Zhao, J., Ung, C.O.L. et al. Obstacles and opportunities the United States come from China or India. Trump’s proin Chinese pharmaceutical innovation, 2017 posed 25% tariff on apis produced in China would encour-
[7] Niels Graham, 2023 age generic drug manufacturers to source apis outside of
[8] Claire Klobucista and Mariel Ferragamo, 2023 China, while also spurring an overall increase in API pric-
[9] GlobalData Healthcare, 2018
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
